Parkinson's Disease
A neurodegenerative disorder characterized by loss of dopaminergic neurons in the substantia nigra, causing motor symptoms (tremor, rigidity, bradykinesia) and non-motor symptoms.
In Depth
The ECS is altered in Parkinson's disease — CB1 receptor density is increased in the basal ganglia, possibly as a compensatory response to dopamine loss. Cannabinoids have shown neuroprotective effects in MPTP and 6-OHDA animal models of Parkinson's. CBD has demonstrated antioxidant and anti-inflammatory properties relevant to Parkinson's pathology. Clinical studies suggest cannabis may improve non-motor symptoms (sleep, pain, anxiety) in Parkinson's patients, with limited evidence for motor symptom improvement.
Related Terms
Further Reading
More in Clinical
Dravet Syndrome
A severe, treatment-resistant form of childhood epilepsy characterized by prolonged seizures, often triggered by fever, beginning in the first year of life.
Lennox-Gastaut Syndrome (LGS)
A severe form of childhood-onset epilepsy characterized by multiple seizure types, slow spike-wave EEG pattern, and cognitive impairment.
Epidiolex
The FDA-approved pharmaceutical formulation of purified cannabidiol (CBD), manufactured by GW Pharmaceuticals (now Jazz Pharmaceuticals). Approved in 2018 for Dravet syndrome and Lennox-Gastaut syndrome.
Dronabinol (Marinol)
A synthetic form of THC (Δ9-tetrahydrocannabinol) approved by the FDA for chemotherapy-induced nausea/vomiting and AIDS-related anorexia.
Nabilone (Cesamet)
A synthetic cannabinoid analogue of THC approved for chemotherapy-induced nausea and vomiting. More potent than dronabinol.